Alto Neuroscience (NYSE:ANRO) Trading Down 5.5% – What’s Next?

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) were down 5.5% during trading on Monday . The company traded as low as $20.34 and last traded at $20.2930. Approximately 243,187 shares traded hands during mid-day trading, an increase of 3% from the average daily volume of 235,854 shares. The stock had previously closed at $21.47.

Analysts Set New Price Targets

A number of research firms recently weighed in on ANRO. BTIG Research raised their target price on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Wall Street Zen cut shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday. Robert W. Baird increased their price objective on shares of Alto Neuroscience from $22.00 to $41.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a research report on Tuesday, March 17th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Alto Neuroscience has an average rating of “Moderate Buy” and a consensus price target of $34.33.

Alto Neuroscience Trading Down 6.6%

The company has a market cap of $640.60 million, a price-to-earnings ratio of -9.20 and a beta of 2.51. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.69 and a current ratio of 15.69. The firm has a fifty day moving average price of $18.47 and a 200 day moving average price of $13.74.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.11. As a group, equities analysts predict that Alto Neuroscience, Inc. will post -2.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently modified their holdings of the company. Commodore Capital LP acquired a new stake in Alto Neuroscience in the 4th quarter valued at about $32,453,000. Perceptive Advisors LLC raised its stake in Alto Neuroscience by 1,048.5% in the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after buying an additional 1,629,027 shares during the period. Vestal Point Capital LP lifted its position in shares of Alto Neuroscience by 161.6% in the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock valued at $44,233,000 after buying an additional 1,535,000 shares during the last quarter. Vivo Capital LLC acquired a new stake in shares of Alto Neuroscience in the fourth quarter valued at approximately $18,433,000. Finally, Ikarian Capital LLC boosted its stake in shares of Alto Neuroscience by 368.2% during the 4th quarter. Ikarian Capital LLC now owns 515,000 shares of the company’s stock worth $9,167,000 after acquiring an additional 405,000 shares during the period.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.